PRESENT ACADEMIC POSITION
     Associate Professor of Pathology, National Cancer Institute, 2002-Now.


QUALIFICATIONS

1. High School Diploma: June 1978.
2. M.B.B.Ch.: From Faculty of Medicine (Kasr-El-Eini), Cairo University. December 1984. Grade: Very Good with Honors.
3. M.Sc. in Pathology: From Faculty of Medicine, Cairo University, October 1991. Grade: Very Good
4. Doctorate Degree in Oncologic Pathology: NCI, Cairo University, May 1996.

PROFESSIONAL EXPERIENCE

In The IT Field

1. Design and development of the pathology data base pplication and coding system at the Pathology Department, NCI, Cairo Universty, 1988.
2. Erection of the pathology local area network, 1989.
3. Member to the committee for the develpoment of the NCI patient information network (256 work stations) funded by the UNDP, 1990-1995.
4. Development of a pathology data base application for use in pathology private labs, 1991
5. 5. External consultant for evaluating the hospital information and management system (a custom made pachage running on IBM S400 system) at Al Salam International Hospital Maadi, 1996.
6. Moderator for the first software and hardware upgrade plan At Al Borg Company, 1997 (Main contractor NCR, Egypt, Value approximately 750, 000 L.E.).
7. Supervising the lab operatoinal module (owned and copywirted by Al Borg Laboratory Company) contineous development project. The project included the re-desing and re-wrighting of this application using Oracle developer 2000 and Sybase Power Builder to have three versions of this module including the original Informix 4GL-Unix based version, 1997-1998.
8. Establishing and heading the Information Technology Unit, Al Borg Laboratory, Egypt, 1998 till now.
9. Supervision the desing and erection of Al Borg Laboratory WAN (with voice and vedio capabilities) connecting 30 branches in Greater Cairo, Delta and Upper Egypt utilizing leased lines, ISDN lines and frame relay technology, 1999-2002.
10. Contracting and supervising the desing and implementation of the closed circuity intelegent interfacing package that interfaces 20 autoanalyzers from seven vendors with lab operational module, 2000-completed 2001.
11. Contracting and supervising the intelegent pateint results verification, central quality assurance, and patient results availability through the internet projects, starting 2002 and expected to be completed 2003.
12. Contracting and supervising the patient's results full autovalidation module which integrates results verification, central quality assurance, delta checks, auto-commenting and automatic printing of of results, strating March 2007 and expected to be completed by the end of same year.

In The Pathology Field

1. One year internship rotation at Cairo University Medical hospitals 1985-1986.
2. Medical Officer at School Health Department, Ministry of Health, Cairo, 1986-1987.
3. Demonstrator of Pathology, National Cancer Institute, Cairo University 1987-1991
4. Surgical Pathologist & Cytopathologist at Prof. Dr. MN El-Bolkainy Private Lab, 1988- till now.
5. Assistant Lecturer of Pathology, National Cancer Institute, Cairo University 1991-1996.
6. Lecturer of Pathology, National Cancer Institute, Cairo University, 1996-2002.
7. Consultant Pathologist & Cytopathologist, As Salam International Hospital, Maadi, Cairo, 1996-.
8. Consultant Pathologist & Cytopathologist, Al Borg Laboratory, Egypt, 1996-.
9. Consultant Pathologist, Dar Al Fouad Hospital, 6th of October, Egypt, 1996-.2000.
10. Head of Information Technology Unit, Al Borg Laboratory, Egypt, 1998-
11. Consultant Pathologist, Al Borg Laboratories, Saudi Araiba, 1999-
12. Assisstant Professor of Pathology, National Cancer Institute, 2002-Now.
13. Consultant Pathologist & Cytopathologist, Dametta Oncology Center 2002-
14. Consultant Cytopathologist, Misr Radiology Center, Cairo, 2002-2006
15. Consultant Pathologist and Cytopathologist, Menia Oncology Center, 2003-
16. Head of Pathology Unit, Al Borg Laboratory, Egypt, 2004-
    

PUBLICATIONS

1. Recurrent Soft Tissue Sarcomas. M. Sc. Thesis, 1991.
2. Proliferative Index and Mutant p53 Overexpression in bladder Cancer: Relation to Survival, Doctorate Degree thesis, 1995.
3. Epidemiology of Cancer, In: Topographic Pathology of Cancer, NCI Cairo (Publisher), M. N. El-Bolkainy (Editor), 1998.
4. Fine needle aspiration of breast lesions. The experience of the Egyptian National Cancer Institute. J Egypt Nat Cancer Inst, Vol. 9, No. 3, pp. 239-246, 1997.
5. Effect of mitomycin-C on different ocular tissues, an experimental study. Cataract and Cornea, Vol. 4, pp. 46-54, 1998.
6. Evaluation of the vital staining technique as an adjunct in the diagnosis and management of oral precancerous and malignant lesions. Proceedings of the VIII International Dental Congress, Cairo Meridian Hotel, March, 1998.
7. Human papilloma virus in Egyptian female genital neoplasms. J Egypt Nat Cancer Inst, Vol. 10, No. 2, pp. 199-205, 1998.
8. Prognostic value of DNA Ploidy and p53 tumor suppressor gene expression in colorectal carcinoma, Sc J Az Med Fac (Girls), Vol. 19, No. 2, pp945-958, 1998.
9. Malignant germ cell tumors in children. Treatment results at the National Cancer Institute, Cairo. J Egypt Nat Cancer Inst, Vol. 10, No. 3, pp. 277-288, 1998.
10. Criteria of differentiation of different follicular thyroidal neoplasmsin fine needle aspiration cytoloyg. J Egypt Pathol, Vol. 18, No. 1, pp227-240, 1998.
11. Ductal versus lobular carcinoma of breast in fine needle aspiration cytology. J Egypt Pathol, Vol. 18, No 2, pp59-78, 1998.
12. C-erbB2 overexpression in breast cancer fine needle aspirates in Egyptian females. J Egypt Soc Path, 19(1):239-247, 1999.
13. Immunohistochemical study of p53 expression and PCNA in astrocytomas. Proceedings of the IV International conferenceof the Mediterranean society of tumor markers oncology, Royal Society of Medicine, London, U.K., July 22-24, 2000.
14. Study of apoptosis in different stages of progression of colonic adenocarcinoma. Proceedings of the IV International conferenceof the Mediterranean society of tumor markers oncology, Royal Society of Medicine, London, U.K., July 22-24, 2000.
15. Prognostic value of human mammaglobin mRNA in breast cancer patients. J Egypt Biochem, 18(2):261-274, 2000.
16. Prognostic implication of angiogenesis, p53, PCNA and DNA ploidy in low-grade superficial transitional cell carcinoma of the urinary bladder: Concordance of relapse and stage progression. J Egypt Soc Path, 20(2), 2000.
17. Significance of mast cells and their subtypes in normal and subfertile human testes: A histological and immunohistochemical study. Egypt J Anat, Vol. 25, No. 2, pp. 239-262, 2002.
18. The prognostic significance of p53, Bcl-2, cytokeratin 20 and Ki-67 in primary superficial papillary transitional bladder carcinoma. J Egypt Nat Cancer Inst, Vol. 15, No. 3, pp. 183-191, 2003.
19. Primary adenocarcinoma of the urinary bladder: Risk factors and value of post-operative radiotherapy. J Egypt Nat Cancer Inst, Vol. 15, No. 3, pp. 193-200, 2003.
20. Immunophenotyping, MIB-1, p53 and mast cell tryptase in Large cell non-Hodgkin's lymphoma. Med J Cairo Univ, Vol. 71, No. 4, Supp. II, pp. 63-74, 2003.
21. A study of E and P-cadherins in breast carcinoma. Egypt J Lab Med, Vol. 16, No. 1, pp. 1-18, 2004.
22. Lymph node metastasis in breast carcinoma: clinicopathological correlations in 3747 patients. J Egypt Natl Canc Inst, Vol. 16, No. 1, pp. 50-56, 2004.
23. Midfacial degloving approach for malignant maxillary tumors. J Egypt Nat Cancer Inst, Vol. 16, No. 2, pp. 69-75, 2004.
24. Multidisciplinary treatment in children with non-metastatic hepatoblastoma: Treatment results at the National Cancer Institute, Cairo University. J Egypt Nat Cancer Inst, Vol. 16, No. 2, pp. 92-98, 2004.
25. Hepatitis C virus and its genotypes and Helicobacter Pylori in Pediatric non-Hodgkin's lymphoma: Could there be a possible etiologic role? J Egypt Nat Cancer Inst, Vol. 16, No. 2, pp. 114-122, 2004.
26. Long term results of primary adenocarcinoma of the urinary bladder: A report of 192 patients. Urol Oncol., Vol. 24, No. 1, pp. 13-20, Jan. 2006.
27. Role of scintimammography in evaluation of treatment response of locally advanced breast cancer (LABC). Proceedings of the 7th Annual Meeting of the Egyptian Society of Nuclear Medicine Specialists (ESNMS), Alexandria, Egypt, March 16-18, 2006.
28. Her2 status in breast cancer determined by IHC and FISH: Experience at NCI-Cairo University, Egypt. Proceedings of the XXVI International Congress of the International Academy of Pathology (hosted by the United states and Canadian Academy of Pathology), Montreal, Quebec, Canada, September 16-21, 2006.

SCIENTIFIC ACTIVITIES

• Conferences
  1. The Second National Symposium on Non-Hodgkin's Lymphomas and Leukemia, Meridian Hotel, April 23, 1987.
  2. The First International Conference of Tumor Markers, Mariott Hotel, 15-17 Feb., 1988.
  3. Member of the Organizing Committee of the International Academy of Pathology, Arab division, 5th Scientific meeting. Gezirah Sheraton Hotel, Cairo. November 6-7 1993.
  4. Member of the Organizing Committee of the International Symposium on Lymphoma and Acute Lymphatic Leukemia. Pullman Hotel, Cairo. November 19-21 1993.
  5. The Second International Cancer Molecular Biology Symposium. Sonesta Hotel. November 24-26 1993.
  6. Egyptian Society of Laboratory Medicine, 5th annual conference. Cairo International Conference Center. January 8-10 1994.
  7. Member of the Organizing Committee of the International Congress on Cancer, Advances in Research and Treatment. Cairo International Conference Center. November 6-11 1994.
  8. Member of the Organizing Committee of International Cancer Conference, Bladder and Prostate Cancer. Beach Albatros, Hurghada, Red Sea, Egypt. January 18-22 1995.
  9. First Pan Arab Cancer Conference, Third French Arab Oncology Meeting, Fourth National Cancer Conference. Le Meridien Le Caire, Cairo, Egypt. March 20-22, 1996.
  10. The VIII International Dental Congress, Cairo Meridian Hotel, March, 1998.
  11. The IV International conferenceof the Mediterranean society of tumor markers oncology, Royal Society of Medicine, London, U.K., July 22-24, 2000.
  12. Egyptian Society of Laboratory Medicine, 11th annual conference. Cairo International Conference Center. January 2000.
  13. Egyptian Society of Laboratory Medicine, 12th annual conference. Cairo International Conference Center. January 2001.
  14. First joint conference of the Egyptian Cancer Socitey, The National Cancer Institue, and Ministery of Health Cancer Centers, Luxor, 2002.
  15. Congress of the Asian Forum of Immunology and Oncology, UNESCO Palace, Beirut, Lebanon, August 21-25, 2002.
  16. The 9th Annual Scientific Congress of the Middle East Fertility Society (MEFS), Cairo, Egypt, October 30 – November 2, 2002.
  17. 15th Congress of the International Academy of Pathology (Arab Division), Cairo, Egypt, October 14-16, 2003.
  18. 2nd Conference of bone marrow trephine biopsy " Recent advances in bone marrow biopsy pathology", Cairo, Egypt, April 6-8, 2004.
  19. II Intercontintal Congress of Pathology, Iguassu Falls, Brazil, June 9-13, 2004.
  
  
  
• Contribution to Books
  1. Cancer Pathology Registry (1985-1989), Mokhtar (editor), Pathology Department, NCI Cairo (Publisher), 1991.
  2. General Pathology of Cancer (1st edition), El-Bolkainy, El-Asdekaa Graphics Center, Cairo, 1991.
  3. Epidemiological, Immunological and Clinical Studies on Lymphoma and Leukemia in Egypt, A Project Report, Principal Investigator M. N. El-Bolkainy, 1994.
  4. Treatment Policy of NCI, A guide to practicing oncologists, NCI Cairo (Publisher), MN El-Bolkainy (Editor), 1994.
  5. Topographic Pathology of Cancer (1st & 2nd editions), NCI Cairo (publisher), MN El-Bolkainy (Editor), 1998 & 2000.
  6. Topographic Pathology of Cancer 3rd edition, MN El-Bolkainy, MA Nouh and TN El-Bokainy (Publishers and Editors), 2005.
  7. General Pathology of Cancer 2nd edition, NCI Cairo (publisher), MN El-Bolkainy, MA Nouh and TN El-Bolkiany (Editors), 2006.
  
  
  
• Research Projects
  • Epidemiological and clinical studies on lymphomas & leukemias, at National Cancer Institute,  A collaborative research project between The National Cancer Institute, Cairo and The National Cancer Institute, NIH, Bethesda, Maryland, USA. Supported by : Egypt-US Health Agreement USAID: PASA: 263-0102-1013. Principal Investigator M. N. El-Bolkainy, Cairo University, 1982-1993.
  • End Results of Bladder Cancer treatment, USA-NCI Funds, Principal Investigator A. El-Said, 1977- till now.
  
  
  
• Thesis Supervision
  • Eleven M.D. theses (six accepted and five are current) and two M.Sc. thesis (both accepted).

Back to Al Borg Laboratory Staff